Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia

Area of Science:

• Molecular Biology
• Epigenetics
• Hematologic Malignancies

Background:

• Transcriptional deregulation is crucial in acute myeloid leukemia (AML).
• Identifying epigenetic modifiers is key to understanding AML biology and developing therapies.
• PRMT1 (protein arginine methyltransferase 1) and KDM4C are epigenetic enzymes implicated in cancer.

Purpose of the Study:

• To investigate the functional role of PRMT1 in various MLL and non-MLL leukemias.
• To explore the therapeutic potential of targeting PRMT1 and KDM4C in AML.
• To elucidate the aberrant epigenetic circuitry involving PRMT1 and KDM4C in acute leukemia.

Main Methods:

• Experimental validation of PRMT1 involvement in leukemic transformation.
• Assessment of KDM4C co-recruitment by chimeric transcription factors.
• Pharmacological inhibition of KDM4C and PRMT1 in leukemia models.
• Analysis of transcriptional and transformation suppression.

Main Results:

• PRMT1 is essential, but not sufficient, for leukemic transformation.
• Chimeric transcription factors co-recruit KDM4C, an H3K9 demethylase, for epigenetic reprogramming.
• Pharmacological inhibition of KDM4C/PRMT1 effectively suppresses transcription and transformation in MLL fusions and MOZ-TIF2 leukemias.
• A tractable aberrant epigenetic circuitry mediated by KDM4C and PRMT1 was identified.

Conclusions:

• PRMT1 and KDM4C play critical roles in the epigenetic reprogramming driving acute leukemia.
• Targeting the KDM4C/PRMT1 axis represents a promising therapeutic strategy for AML.
• Understanding this aberrant epigenetic circuitry offers new avenues for AML treatment.